$IMTX News
Last published 1d ago
- 1d agoIMTXImmatics Announces Third Quarter 2026 Financial Results and Business UpdateGlobeNewswireHouston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended September 30, 2026.
- 2w agoIMTXImmatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingGlobeNewswireIMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of
- 2mo agoIMTXImmatics Announces $150 Million Underwritten OfferingGlobeNewswireHouston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs
- 2mo agoIMTXImmatics Announces Second Quarter 2026 Financial Results and Business UpdateGlobeNewswireEnrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint;
- 3mo agoIMTXImmatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026GlobeNewswireHouston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs
- 5mo agoIMTXImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingGlobeNewswireOne-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal
- 5mo agoIMTXImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung CancerGlobeNewswireIMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment
- 5mo agoIMTXImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual MeetingGlobeNewswireOne-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective
- 6mo agoIMTXImmatics Announces First Quarter 2026 Financial Results and Business UpdateGlobeNewswireSUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027Multiple key clinical data sets
- 6mo agoIMTXImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual MeetingGlobeNewswireHouston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell
- 6mo agoIMTXPRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaGlobeNewswireIndividual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by
- 8mo agoIMTXImmatics Announces Full Year 2025 Financial Results and Business UpdateGlobeNewswireAnzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the
- 11mo agoIMTXImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 CongressGlobeNewswireIMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced
- 11mo agoIMTXImmatics Announces Third Quarter 2025 Financial Results and Business UpdateGlobeNewswireAnzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026
- 12mo agoIMTXImmatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development StepsGlobeNewswireCompany to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily
- 1y agoIMTXImmatics Appoints Amie Krause as Chief People OfficerGlobeNewswireHouston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today
- 1y agoIMTXImmatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential SymposiumGlobeNewswireOne-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more mature
- 1y agoIMTXImmatics Appoints Venkat Ramanan as Chief Financial OfficerGlobeNewswireHouston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today
- 1y agoIMTXImmatics Announces Second Quarter 2025 Financial Results and Business UpdateGlobeNewswireAnzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with
- 1y agoIMTXImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic MelanomaGlobeNewswireExtended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable
- 1y agoIMTXImmatics Announces First Quarter 2025 Financial Results and Business UpdateGlobeNewswireIMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial
- 1y agoIMTXImmatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual MeetingGlobeNewswireHouston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting
- 1y agoIMTXImmatics Announces Full Year 2024 Financial Results and Business UpdateGlobeNewswireRandomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoIMTXImmatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEGlobeNewswireThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR
- 2y agoIMTXImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMEGlobeNewswireTwo oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics' TCR-T PRAME franchise to target solid cancers ACTengine®
- 2y agoIMTXImmatics Announces Pricing of $150 Million Public OfferingGlobeNewswireHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer
- 2y agoIMTXImmatics Announces Proposed $150 Million Public OfferingGlobeNewswireHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer
- 2y agoIMTXImmatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 TrialGlobeNewswireCompany to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated
- 2y agoIMTXImmatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024GlobeNewswireHouston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting
- 2y agoBMYIMTXImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development UpdateGlobeNewswireTCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various
- 2y agoIMTXImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024GlobeNewswireHouston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T
- 2y agoIMTXImmatics Announces Second Quarter 2024 Financial Results and Business UpdateGlobeNewswireClinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months;
- 2y agoIMTXImmatics Appoints Alise Reicin to Board of DirectorsGlobeNewswireHouston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting
- 2y agoIMTXImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024GlobeNewswireHouston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer
- 2y agoIMTXIRWDALDRVECTMemo Therapeutics AG appoints Paul Carter as ChairpersonGlobeNewswirePRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market
- 2y agoIMTXImmatics Announces First Quarter 2024 Financial Results and Business UpdateGlobeNewswireCompany Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated
- 2y agoIMTXImmatics Announces Full Year 2023 Financial Results and Corporate UpdateGlobeNewswireInterim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4
- 2y agoIMTXImmatics Announces Pricing of $175 Million Public OfferingGlobeNewswireHouston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer
- 2y agoIMTXImmatics Announces Proposed Public OfferingGlobeNewswireHouston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer
- 2y agoCOYAREPLIMTXDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingPR NewswireDISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in...
- 2y agoIMCRIMTXPLXFSTXLevicept Appoints Eliot Forster as CEOGlobeNewswireLeadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a
- 2y agoIMTXImmatics Announces Third Quarter 2023 Financial Results and Business UpdateGlobeNewswireACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including responses ongoing at
- 3y agoIMTXImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialGlobeNewswireCompany to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today,
- 3y agoIMTXImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyGlobeNewswireRMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities underway with an
- 3y agoIMTXPLXProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of DirectorsPR NewswireAppointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors
- 3y agoBABATWNKMRNAIMTX+13Stocks making the biggest moves midday: Tesla, Qualcomm, Meta, Moderna and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoIMTXMRNAModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsGlobeNewswireCollaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA
- 3y agoIMTXMRNAModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsACCESS NewswireCollaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA
- 3y agoIMTXImmatics Announces Second Quarter 2023 Financial Results and Business UpdateGlobeNewswirePhase 1/2 clinical trial initiated evaluating Immatics' second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67%